Compare Regeneron Pharmaceuticals Inc (REGN) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Advanced Drainage Systems Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Advanced Drainage Systems Inc trades at $141.75 (market cap $10.64B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.7× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| REGN | WMS | |
|---|---|---|
Market Cap | $70.79B | $10.64B |
Sector | Health | Industrials |
52-Week High | $812.27 | $175.38 |
52-Week Low | $545.46 | $113.04 |
Enterprise Value | $64.74B | $12.21B |
Dividend Yield | 0.56% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
WMS (Advanced Drainage Systems) trades at $138.74, down 5.97% on the day, with a bearish technical signal. The company shows solid fundamentals with a 13.98% net income margin and consistent earnings beats in recent quarters, though 2025 revenue was flat at $2.90B. Recent news includes a dividend increase and upcoming Q1 FY2027 results on August 6, 2026.
The stock presents a mixed outlook. Strong profitability and a consensus price target of $184.43 suggest upside potential, but near-term headwinds include a bearish technical setup and projected earnings decline in 2026. Key risks are execution on investments and competitive pressures in the water management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
